Banff 2022 Kidney Commentary: Reflections and Future Directions

被引:1
|
作者
Rabant, Marion [1 ]
Adam, Benjamin A. [2 ]
Aubert, Olivier [3 ]
Boehmig, Georg A. [4 ]
Clahsen Van-Groningen, Marian [5 ,6 ]
Cornell, Lynn D. [7 ]
de Vries, Aiko P. J. [8 ,9 ]
Huang, Edmund [10 ]
Kozakowski, Nicolas [11 ]
Perkowska-Ptasinska, Agnieszka [12 ]
Riella, Leonardo V. [13 ]
Rosales, Ivy A. [14 ]
Schinstock, Carrie [15 ]
Simmonds, Naomi [16 ]
Thaunat, Olivier [17 ]
Willicombe, Michelle [18 ]
机构
[1] Necker Enfants Malad Hosp, Assistance Publ Hop Paris, Dept Radiol, Paris, France
[2] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[3] Necker Enfants Malad Hosp, Assistance Publ Hop Paris, Kidney Transplantat Dept, Paris, France
[4] Med Univ Vienna, Dept Med 3, Vienna, Austria
[5] Erasmus MC, Transplant Inst, Dept Pathol & Clin Bioinformat, Rotterdam, Netherlands
[6] RWTH Aachen Univ Hosp, Inst Expt Med & Syst Biol, Aachen, Germany
[7] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55906 USA
[8] Leiden Univ Med Ctr, Dept Med, Div Nephrol, Leiden, Netherlands
[9] Leiden Univ Med Ctr, Leiden Transplant Ctr, Leiden, Netherlands
[10] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA USA
[11] Med Univ Vienna, Dept Pathol, Vienna, Austria
[12] Med Univ Warsaw, Dept Pathol, Warsaw, Poland
[13] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Nephrol Div, Boston, MA 02115 USA
[14] Harvard Med Sch, Massachusetts Gen Hosp, Massachusetts Gen Hosp, Boston, MA USA
[15] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN USA
[16] Guys & St ThomasNHS Fdn Trust, Dept Hematol, London, England
[17] Hosp Civils Lyon, Edouard Herriot Hosp, Dept Transplantat Nephrol & Clin Immunol, Lyon, France
[18] Hammersmith Hosp, Imperial Coll, Renal & Transplant Ctr, Imperial Coll Healthcare NHS Trust, London, England
关键词
ANTIBODY-MEDIATED REJECTION;
D O I
10.1097/TP.0000000000005112
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely "microvascular inflammation/injury donor-specific antibodies-negative and C4d negative" and "probable antibody-mediated rejection," into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell-mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell-mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.
引用
收藏
页码:292 / 299
页数:8
相关论文
共 50 条